Theresa A Mcdonagh

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7806107/publications.pdf

Version: 2024-02-01

99 papers 17,596 citations

93792 39 h-index 93 g-index

101 all docs

101 docs citations

101 times ranked

15198 citing authors

#	Article	IF	CITATIONS
1	Impact of the COVID-19 pandemic on in-hospital mortality in cardiovascular disease: a meta-analysis. European Journal of Preventive Cardiology, 2022, 29, 1266-1274.	0.8	36
2	Sodium–glucose coâ€transporter 2 inhibitors as an early, firstâ€line therapy in patients with heart failure and reduced ejection fraction. European Journal of Heart Failure, 2022, 24, 431-441.	2.9	67
3	Education and certification on heart failure of the <scp>H</scp> eart <scp>F</scp> ailure <scp>A</scp> ssociation of the <scp>E</scp> uropean <scp>S</scp> ociety of <scp>C</scp> ardiology. European Journal of Heart Failure, 2022, 24, 249-253.	2.9	6
4	A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction–Âinsights from the <scp>ESCâ€HFA EORP</scp> Heart Failure Long‶erm Registry. European Journal of Heart Failure, 2022, 24, 335-350.	2.9	49
5	Implementation of the Mental Capacity Act: a national observational study comparing resultant trends in place of death for older heart failure decedents with or without comorbid dementia. BMC Medicine, 2022, 20, 30.	2.3	1
6	European Society of Cardiology quality indicators for the care and outcomes of adults with heart failure. Developed by the Working Group for Heart Failure Quality Indicators in collaboration with the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2022, 24, 132-142.	2.9	30
7	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2022, 24, 4-131.	2.9	820
8	Patients hospitalised with heart failure across different waves of the COVID-19 pandemic show consistent clinical characteristics and outcomes. International Journal of Cardiology, 2022, 350, 125-129.	0.8	8
9	Predictors of myocardial fibrosis and response to anti-fibrotic therapy in heart failure with preserved ejection fraction. International Journal of Cardiovascular Imaging, 2022, 38, 1569-1578.	0.7	2
10	Data standards for heart failure: the European Unified Registries for Heart Care Evaluation and Randomized Trials (EuroHeart). European Heart Journal, 2022, 43, 2185-2195.	1.0	12
11	Only people with increased plasma concentrations of natriuretic peptides should be included in outcome trials of diabetes, cardiovascular and kidney disease: implications for clinical practice. European Journal of Heart Failure, 2022, 24, 678-680.	2.9	1
12	The â€Ten Commandments' of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2022, 43, 440-441.	1.0	95
13	Cardiovascular outcomes associated with treatment of type 2 diabetes in patients with ischaemic heart failure. ESC Heart Failure, 2022, , .	1.4	2
14	Prevalence, Characteristics, and Outcomes of COVID-19–Associated Acute Myocarditis. Circulation, 2022, 145, 1123-1139.	1.6	118
15	GuÃa ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica. Revista Espanola De Cardiologia, 2022, 75, 523.e1-523.e114.	0.6	40
16	Predicting hospitalisation for heart failure and death in patients with, or at risk of, heart failure before first hospitalisation: a retrospective model development and external validation study. The Lancet Digital Health, 2022, 4, e445-e454.	5.9	8
17	<scp>COVIDâ€19</scp> and heart failure: the dark side of the moon. European Journal of Heart Failure, 2022, 24, 1129-1131.	2.9	4
18	Practical Guidance for Diagnosing and Treating Iron Deficiency in Patients with Heart Failure: Why, Who and How?. Journal of Clinical Medicine, 2022, 11, 2976.	1.0	5

#	Article	IF	Citations
19	Cardiovascular Damage in COVID-19: What We Know Two Years Later. Current Cardiology Reports, 2022, 24, 1085-1091.	1.3	4
20	Exploring the prevalence, impact and experience of cardiac cachexia in patients with advanced heart failure and their caregivers: A sequential phased study. Palliative Medicine, 2022, 36, 1118-1128.	1.3	3
21	Development, validation, and implementation of biomarker testing in cardiovascular medicine state-of-the-art: proceedings of the European Society of Cardiology—Cardiovascular Round Table. Cardiovascular Research, 2021, 117, 1248-1256.	1.8	11
22	The collateral cardiovascular damage of COVID-19: only history will reveal the depth of the iceberg. European Heart Journal, 2021, 42, 1524-1527.	1.0	21
23	Excess deaths in people with cardiovascular diseases during the COVID-19 pandemic. European Journal of Preventive Cardiology, 2021, 28, 1599-1609.	0.8	93
24	ST2 in patients with severe aortic stenosis and heart failure. Cardiology Journal, 2021, 28, 129-135.	0.5	10
25	68 Implantable cardioverter-defibrillator deactivation in the community: the perspective of palliative care professionals., 2021,,.		0
26	The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC. European Heart Journal, 2021, 42, 1254-1269.	1.0	78
27	New horizons in cardiogeriatrics: geriatricians and heart failure careâ€"the custard in the tart, not the icing on the cake. Age and Ageing, 2021, 50, 1064-1068.	0.7	2
28	Substantial decline in hospital admissions for heart failure accompanied by increased community mortality during COVID-19 pandemic. European Heart Journal Quality of Care & Clinical Outcomes, 2021, 7, 378-387.	1.8	52
29	Safety and Efficacy of Intravenous Ferric Derisomaltose Compared to Iron Sucrose for Iron Deficiency Anemia in Patients with Chronic Kidney Disease With and Without Heart Failure. American Journal of Cardiology, 2021, 152, 138-145.	0.7	11
30	Clozapine-induced myocarditis: electronic health register analysis of incidence, timing, clinical markers and diagnostic accuracy. British Journal of Psychiatry, 2021, 219, 644-651.	1.7	16
31	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2021, 42, 3599-3726.	1.0	5,558
32	Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trial. Nature Medicine, 2021, 27, 1477-1482.	15.2	92
33	Longâ€term outcomes after heart failure hospitalization during the COVIDâ€19 pandemic: a multisite report from heart failure referral centers in London. ESC Heart Failure, 2021, 8, 4701-4704.	1.4	14
34	The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. European Heart Journal, 2021, 42, 3011-3020.	1.0	71
35	Association between ethnicity and degree of improvement in cardiac function following initiation of sacubitril/valsartan. Journal of Cardiovascular Medicine, 2021, Publish Ahead of Print, 37-41.	0.6	3
36	7â€Predictors of myocardial fibrosis and response to anti-fibrotic therapy in heart failure with preserved ejection fraction. , 2021, , .		1

#	Article	IF	CITATIONS
37	Sex†and ageâ€related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Longâ€Term Registry. European Journal of Heart Failure, 2020, 22, 92-102.	2.9	81
38	The year in cardiology: heart failure. European Heart Journal, 2020, 41, 1232-1248.	1.0	11
39	International Consortium for Health Outcomes Measurement (ICHOM): Standardized Patient-Centered OutcomesÂMeasurement Set for HeartÂFailure Patients. JACC: Heart Failure, 2020, 8, 212-222.	1.9	69
40	Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet, The, 2020, 396, 1895-1904.	6.3	425
41	Palliative Care in Acute Heart Failure. Current Heart Failure Reports, 2020, 17, 424-437.	1.3	6
42	Temporal trends in decompensated heart failure and outcomes during <scp>COVID</scp> â€19: a multisite report from heart failure referral centres in <scp>London</scp> . European Journal of Heart Failure, 2020, 22, 2219-2224.	2.9	86
43	The impact of <scp>COVID</scp> â€19 on heart failure hospitalization and management: report from a Heart Failure Unit in London during the peak of the pandemic. European Journal of Heart Failure, 2020, 22, 978-984.	2.9	156
44	Cardiology after COVID-19: Quo Vademus?. European Heart Journal Quality of Care & Clinical Outcomes, 2020, 6, 208-209.	1.8	4
45	Is heart failure misdiagnosed in hospitalized patients with preserved ejection fraction? From the European Society of Cardiology â€∙Heart Failure Association EURObservational Research Programme Heart Failure Longâ€√erm Registry. ESC Heart Failure, 2020, 7, 2098-2112.	1.4	23
46	Unravelling the interplay between hyperkalaemia, renin–angiotensin–aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESCâ€HFAâ€EORP Heart Failure Longâ€Term Registry. European Journal of Heart Failure, 2020, 22, 1378-1389.	2.9	83
47	Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESCâ€EORP Heart Failure Longâ€Term Registry. European Journal of Heart Failure, 2020, 22, 1424-1437.	2.9	36
48	The year in cardiology 2019: heart failure. Revista Romana De Cardiologie, 2020, 30, 185-204.	0.0	0
49	2018 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal, 2019, 40, 87-165.	1.0	4,537
50	Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21, 272-285.	2.9	182
51	Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21, 1169-1186.	2.9	490
52	Sacubitril/valsartan eligibility and outcomes in the ESCâ€EORPâ€HFA Heart Failure Longâ€Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGMâ€HF trial, ESC guidelines, and real world. European Journal of Heart Failure, 2019, 21, 1383-1397.	2.9	35
53	Pirfenidone in Heart Failure with Preserved Ejection Fraction—Rationale and Design of the PIROUETTE Trial. Cardiovascular Drugs and Therapy, 2019, 33, 461-470.	1.3	48
54	Effect of Iron Isomaltoside on Skeletal Muscle Energetics in Patients With Chronic Heart Failure and Iron Deficiency. Circulation, 2019, 139, 2386-2398.	1.6	106

#	Article	IF	CITATIONS
55	Rationale and design of the AFFIRMâ€AHF trial: a randomised, doubleâ€blind, placeboâ€controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in ironâ€deficient patients admitted for acute heart failure. European Journal of Heart Failure, 2019, 21, 1651-1658.	2.9	42
56	Less invasive ventricular reconstruction for ischaemic heart failure. European Journal of Heart Failure, 2019, 21, 1638-1650.	2.9	41
57	Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 853-872.	2.9	434
58	Daily home BNP monitoring in heart failure for prediction of impending clinical deterioration: results from the HOME HF study. European Journal of Heart Failure, 2018, 20, 474-480.	2.9	19
59	A cost effectiveness study establishing the impact and accuracy of implementing the NICE guidelines lowering plasma NTproBNP threshold in patients with clinically suspected heart failure at our institution. International Journal of Cardiology, 2018, 257, 131-136.	0.8	1
60	Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Heart, 2018, 104, 407-415.	1,2	107
61	6â€Comparing echocardiography and cardiac magnetic resonance measures of ejection fraction: implications for HFMRF research. , 2018, , .		7
62	Comparison of the Diagnostic Accuracy of Plasma N-Terminal Pro-Brain Natriuretic Peptide in Patients <80 to those >80 Years of Age with Heart Failure. American Journal of Cardiology, 2018, 122, 2075-2079.	0.7	4
63	Screening, diagnosis and treatment of iron deficiency in chronic heart failure: putting the 2016 European Society of Cardiology heart failure guidelines into clinical practice. European Journal of Heart Failure, 2018, 20, 1664-1672.	2.9	92
64	Mortality after admission for heart failure in the UK compared with Japan. Open Heart, 2018, 5, e000811.	0.9	10
65	Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 1505-1535.	2.9	555
66	Percutaneous Revascularization for Ischemic Ventricular Dysfunction: Rationale and Design of the REVIVED-BCIS2 Trial. JACC: Heart Failure, 2018, 6, 517-526.	1.9	59
67	Validation of U.S. mortality prediction models for hospitalized heart failure in the United Kingdom and Japan. European Journal of Heart Failure, 2018, 20, 1179-1190.	2.9	21
68	B-type natriuretic peptide-guided therapy for heart failure (HF): a systematic review and meta-analysis of individual participant data (IPD) and aggregate data. Systematic Reviews, 2018, 7, 112.	2.5	27
69	Referral for Specialist Follow-up and Its Association With Post-discharge Mortality Among Patients With Systolic Heart Failure (from the National Heart Failure Audit for England and Wales). American Journal of Cardiology, 2017, 119, 440-444.	0.7	21
70	Variation in hospital performance for heart failure management in the National Heart Failure Audit for England and Wales. Heart, 2017, 103, 55-62.	1.2	17
71	MICE or NICE? An economic evaluation of clinical decision rules in the diagnosis of heart failure in primary care. International Journal of Cardiology, 2017, 241, 255-261.	0.8	11
72	Identifying patients with less potential to benefit from implantable cardioverter-defibrillator therapy: comparison of the performance of four risk scoring systems. Journal of Interventional Cardiac Electrophysiology, 2017, 49, 181-189.	0.6	2

#	Article	IF	CITATIONS
73	Biological Phenotypes of Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 2017, 70, 2186-2200.	1.2	159
74	Effectiveness and cost-effectiveness of serum B-type natriuretic peptide testing and monitoring in patients with heart failure in primary and secondary care: an evidence synthesis, cohort study and cost-effectiveness model. Health Technology Assessment, 2017, 21, 1-150.	1.3	21
75	Biologic Variability of Soluble ST2 in Patients With Stable Chronic Heart Failure and Implications for Monitoring. American Journal of Cardiology, 2016, 118, 95-98.	0.7	18
76	Traditional and new composite endpoints inÂheart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency. European Journal of Heart Failure, 2016, 18, 482-489.	2.9	74
77	The healthcare costs of heart failure during the last five years of life: A retrospective cohort study. International Journal of Cardiology, 2016, 224, 132-138.	0.8	35
78	Ironing out iron deficiency in heart failure. European Journal of Heart Failure, 2016, 18, 796-797.	2.9	4
79	Heart Failure Association of the European Society of Cardiology heart failure nurse curriculum. European Journal of Heart Failure, 2016, 18, 736-743.	2.9	61
80	Heart failure specialization in Europe. European Journal of Heart Failure, 2016, 18, 347-349.	2.9	9
81	Treatment of heart failure in adult congenital heart disease: a position paper of the Working Group of Grown-Up Congenital Heart Disease and the Heart Failure Association of the European Society of Cardiology. European Heart Journal, 2016, 37, 1419-1427.	1.0	165
82	Serial galectin-3 for the monitoring of optimally treated stable chronic heart failure: A pilot study. International Journal of Cardiology, 2016, 207, 279-281.	0.8	11
83	Recommendations on preâ€hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. European Journal of Heart Failure, 2015, 17, 544-558.	2.9	315
84	Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine – short version. European Heart Journal, 2015, 36, 1958-1966.	1.0	105
85	Appropriateness criteria for cardiovascular imaging use in heart failure: report of literature review. European Heart Journal Cardiovascular Imaging, 2015, 16, 147-153.	0.5	34
86	Iron therapy for the treatment of iron deficiency in chronic heart failure: intravenous or oral?. European Journal of Heart Failure, 2015, 17, 248-262.	2.9	115
87	Serial soluble ST2 for the monitoring of pharmacologically optimised chronic stable heart failure. International Journal of Cardiology, 2015, 178, 284-291.	0.8	26
88	43â€Acute Heart Failure: Where did We Get Wrong?. Heart, 2015, 101, A25.1-A25.	1,2	0
89	Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. European Heart Journal, 2015, 36, 657-668.	1.0	902
90	Chemotherapy-related Cardiomyopathy. European Cardiology Review, 2015, 10, 19.	0.7	20

#	Article	IF	Citations
91	Heart Failure Association of the <scp>European Society of Cardiology</scp> Specialist Heart Failure Curriculum. European Journal of Heart Failure, 2014, 16, 151-162.	2.9	52
92	Rationale and design of the CONFIRMâ€HF study: a doubleâ€blind, randomized, placeboâ€controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency. ESC Heart Failure, 2014, 1, 52-58.	1.4	38
93	Impact of prolonged implantable cardioverter-defibrillator arrhythmia detection times on outcomes: A meta-analysis. Heart Rhythm, 2014, 11, 828-835.	0.3	44
94	Rationale and design of the CONFIRM-HF study: a double-blind, randomized, placebo-controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency. ESC Heart Failure, 2014, 1 , n/a - n/a .	1.4	1
95	The Year in Cardiology 2012: heart failure. European Heart Journal, 2013, 34, 499-502.	1.0	0
96	The national heart failure audit for England and Wales 2008-2009. Heart, 2011, 97, 876-886.	1.2	128
97	Clinical trials in acute heart failure: simpler solutions to complex problems. Consensus document arising from a European Society of Cardiology cardiovascular round-table think tank on acute heart failure, 12 May 2009. European Journal of Heart Failure, 2011, 13, 1253-1260.	2.9	32
98	Renal dysfunction, as measured by the modification of diet in renal disease equations, and outcome in patients with advanced heart failure. European Heart Journal, 2007, 28, 3027-3033.	1.0	30
99	Characteristics Associated With Growth Differentiation Factor 15 in Heart Failure With Preserved Ejection Fraction and the Impact of Pirfenidone. Journal of the American Heart Association, 0, , .	1.6	2